Guggenheim keeps Buy rating and $40 price target on BLSM
Guggenheim maintained a Buy rating on BlossomHill Therapeutics with a $40.00 price target, implying 55.4% upside versus the Sep 18 close of $25.74.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.